Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Investors can access Lexeo’s Stifel 2026 Virtual Cardiometabolic Forum fireside chat via live webcast and on-demand replay on the company website.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lexeo Therapeutics (LXEO) will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026, at 9:00 a.m. ET.
The discussion will be webcast live under the Events & Presentations tab in the Investors section of the company’s website. A replay of the webcast will be available on the Lexeo website following the presentation, allowing those who cannot attend live to view the session later.
Details
Market move: LXEO -13.51% in the Sep 23 session. Cardiometabolic forum participation
On Sep 23, the day this news came out, LXEO closed 13.51% below the previous close. Argus tracked a trough of -13.7% from its starting point during tracking. Our momentum scanner recorded 71 alerts for this stock that day. That session’s volume was 2.7x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Sep 23 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.
The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Media Response:
Media@lexeotx.com
Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How can investors watch Lexeo Therapeutics’ presentation at the Stifel 2026 Virtual Cardiometabolic Forum?
The fireside chat will be webcast live under the Events & Presentations tab in the Investors section of Lexeo Therapeutics’ website. A replay of the webcast will also be available on the company’s website after the presentation.
When is Lexeo Therapeutics scheduled to present at the Stifel 2026 Virtual Cardiometabolic Forum?
Lexeo Therapeutics is scheduled to participate in a fireside chat on September 30, 2026, at 9:00 a.m. Eastern Time.